Low incidence of acute GVHD and relapse in standard risk patients undergoing allogeneic transplantation with CSA and MTX prophylaxis

被引：0
|
作者：
Byrne, JL [1 ]
Stainer, C [1 ]
Miflin, G [1 ]
Haynes, AP [1 ]
Russell, NH [1 ]
机构：
[1] City Hosp Nottingham, Nottingham, England
来源：
BONE MARROW TRANSPLANTATION | 1998年 / 21卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
409
引用
收藏
页码：S118 / S118
页数：1
相关论文
共 50 条
  • [1] ABO incompatibility and relapse risk in patients undergoing allogeneic marrow transplantation for acute myeloid leukemia
    M Mielcarek
    B Torok-Storb
    R Storb
    Bone Marrow Transplantation, 2002, 30 : 547 - 548
  • [2] ABO incompatibility and relapse risk in patients undergoing allogeneic marrow transplantation for acute myeloid leukemia
    Mielcarek, M
    Torok-Storb, B
    Storb, R
    BONE MARROW TRANSPLANTATION, 2002, 30 (08) : 547 - 548
  • [3] Mycophenolate mofetil in combination with cyclosporine a (CSA) ± prednisolone versus CsA, methotrexate ± prednisolone for the prophylaxis of acute GvHD after allogeneic stem cell transplantation -: MMF, a new option in GvHD prophylaxis.
    Kiehl, MG
    Linck, D
    Schaefer-Eckart, K
    Kroeger, M
    Bronhaeuser, M
    Blau, IW
    Wandt, H
    Jenke, A
    Kienast, J
    Armstrong, VW
    Basara, N
    Schroeder, H
    Kraut, L
    Fauser, AA
    BLOOD, 2003, 102 (11) : 716A - 716A
  • [4] Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation
    Shaughnessy, P. J.
    Bolwell, B. J.
    van Besien, K.
    Mistrik, M.
    Grigg, A.
    Dodds, A.
    Prince, H. M.
    Durrant, S.
    Ilhan, O.
    Parenti, D.
    Gallo, J.
    Foss, F.
    Apperley, J.
    Zhang, M-J
    Horowitz, M. M.
    Abhyankar, S.
    BONE MARROW TRANSPLANTATION, 2010, 45 (06) : 1068 - 1076
  • [5] Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation
    P J Shaughnessy
    B J Bolwell
    K van Besien
    M Mistrik
    A Grigg
    A Dodds
    H M Prince
    S Durrant
    O Ilhan
    D Parenti
    J Gallo
    F Foss
    J Apperley
    M-J Zhang
    M M Horowitz
    S Abhyankar
    Bone Marrow Transplantation, 2010, 45 : 1068 - 1076
  • [6] Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis
    Lai, Y.
    Ma, J.
    Schwarzenberger, P.
    Li, W.
    Cai, Z.
    Zhou, J.
    Peng, Z.
    Yang, J.
    Luo, L.
    Luo, J.
    Deng, D.
    Li, Q.
    Zhou, Y.
    Liang, J.
    BONE MARROW TRANSPLANTATION, 2009, 43 (01) : 61 - 67
  • [7] Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis
    Y Lai
    J Ma
    P Schwarzenberger
    W Li
    Z Cai
    J Zhou
    Z Peng
    J Yang
    L Luo
    J Luo
    D Deng
    Q Li
    Y Zhou
    J Liang
    Bone Marrow Transplantation, 2009, 43 : 61 - 67
  • [8] Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia
    Kinsella, Francesca A. M.
    Maroto, Maria A. L.
    Loke, Justin
    Craddock, Charles
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (06) : 2173 - 2183
  • [9] Mycophenolate mofetil and CSA as GVHD prophylaxis after allogeneic blood stem cell transplantation.
    Bornhauser, M
    Thiede, HM
    Schuler, SU
    Thiede, C
    Ehninger, G
    BONE MARROW TRANSPLANTATION, 1998, 21 : S117 - S117
  • [10] Similar Risk of Relapse and Survival with Post-Transplant Cyclophosphamide Compared to Standard Gvhd Prophylaxis after Allogeneic Hematopoietic Cell Transplantation for AML and MDS
    Yasin, Hassaan
    Naqvi, Mahrukh
    Kim, Jongphil
    Faramand, Rawan
    Puglianini, Omar Alexis Castaneda
    Khimani, Farhad
    Lazaryan, Aleksandr
    Nishihori, Taiga
    Nieder, Michael
    Pidala, Joseph
    Bejanyan, Nelli
    BLOOD, 2022, 140 : 4886 - 4888
12345